- Conditions
- Colorectal Cancer, Gastric Cancer, Locally Advanced or Metastatic Solid Tumors, Pancreatic Cancer
- Interventions
- MRG007
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Colorectal Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Colorectal Cancer. Browse Colorectal Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 22, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
How Colorectal Cancer studies are organized in the registry
Records may be registered under “colorectal,” “colon,” or “rectal” cancer — the three terms overlap but are not interchangeable in search, so check more than one if your interest spans them. Molecular labels (MSI-high, KRAS, BRAF) and the abbreviation mCRC for metastatic disease appear frequently in titles.
- 18% of the 650 locally indexed Colorectal Cancer records are currently marked recruiting.
- The most common phase group in the local index is Phase 1 (246 records).
- The most frequent sponsor is Memorial Sloan Kettering Cancer Center (25 records).
- The most listed study location is New York, New York (149 records).
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Phase distribution
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Colorectal Cancer
- Interventions
- Fruquintinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more
- Conditions
- Colorectal Cancer, Minimal Residual Disease
- Interventions
- Cetuximab, Cyclophosphamide, Fludarabine Phosphate, Lymphodepleting Chemotherapy, Rimiducid (AP1903), TROP2-CAR-NK Cells
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult
- Interventions
- CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Drug
- Lead sponsor
- Crossignal Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- CRC, Cancer, Colon Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Lung Cancer, MESOM, Mesothelioma, Mesothelioma, Malignant, NSCLC, NSCLC, Recurrent, Non Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Pancreas Cancer, Pancreatic Neoplasm, Rectal Cancer, Solid Tumor, Adult
- Interventions
- A2B543, A2B694, xT CDx with HLA-LOH Assay
- Biological · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Colorectal Cancer, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor
- Interventions
- ASP5834, panitumumab
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
- Conditions
- Colorectal Cancer
- Interventions
- Standard of Care, Telisotuzumab Adizutecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Fullerton, California • Los Angeles, California + 17 more
- Conditions
- Colorectal Cancer
- Interventions
- 5-Fluorouracil, Bevacizumab, Leucovorin, ONO-4578, Opdivo®, Oxaliplatin
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Gastric Cancers, Pancreatic Cancer
- Interventions
- BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Drug
- Lead sponsor
- Bold Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Tampa, Florida
- Conditions
- Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Minimal Residual Disease, Tislelizumab, ctDNA
- Interventions
- Fruquintinib, Tislelizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Liver Metastases
- Interventions
- AGEN1423, Balstilimab, Botensilimab, Radiation
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- High Cysteine Diet, Low Cysteine Diet
- Other
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • West Lafayette, Indiana
About this Colorectal Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Colorectal Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Colorectal Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Colorectal Cancer.